Alx Oncology Holdings Inc. ALXO
Biotechnology: Pharmaceutical Preparations · IPO 2020 · data as of November 13, 2026
Alx Oncology Holdings Inc. (ALXO) is a healthcare company listed in the US with a market value of about $130M.
Its overall Stock Analiz score is 0.4 out of 5 (weak). The strongest part is financial health (2/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -103%.
About Alx Oncology
Alx Oncology is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2020. It was profitable in 0 of the last 8 years in our data. Its share count rose by 32% over three years (dilution for shareholders).
Score: 0.4 / 5
Checks passed
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 8 years
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | $0 | $0 | $1M | $5M | $2M |
| Net income | -$102M | -$135M | -$161M | -$123M | -$83M | -$46M | -$19M | -$14M |
| Free cash flow | -$84M | -$122M | -$132M | -$91M | -$69M | -$38M | -$15M | -$14M |
| EPS (diluted) | $-1.90 | $-2.58 | $-3.74 | $-3.03 | $-2.07 | $-2.76 | $-7.56 | $-6.33 |
| Net margin | — | — | — | — | — | -3869.7% | -401.2% | -664.3% |
| ROIC | -262.6% | -110.8% | -82.8% | -35.9% | -22.9% | -8.0% | — | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
Does Alx Oncology pay a dividend?
Not currently.
Is Alx Oncology a good stock to buy?
We do not give buy or sell advice. Alx Oncology scores 0.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.